ArticleEMBO molecular medicine2017
Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target
Article in EMBO molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- An Israeli tuberous sclerosis cohort: the efficacy of different anti-epileptic strategies.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Article
- HSPA12A is required for adipocyte differentiation and diet-induced obesity through a positive feedback regulation with PPARγ.Cell death and differentiation · 2019Article
- NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target.Oncogenesis · 2019Article
- Bladder drug mirabegron exacerbates atherosclerosis through activation of brown fat-mediated lipolysis.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Diablo: A Double-Edged Sword in Cancer?Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- mTORC1 Inhibition Is an Effective Treatment for Sporadic Renal Angiomyolipoma.Kidney international reports · 2018Article
- Renal lineage cells as a source for renal regeneration.Pediatric research · 2018Review
- Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic targetEMBO molecular medicine · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
22 authors at 4 institutions in 2 countries.
Funding
Abstract
Angiomyolipoma (AML), the most common benign renal tumor, can result in severe morbidity from hemorrhage and renal failure. While mTORC1 activation is involved in its growth, mTORC1 inhibitors fail to eradicate AML, highlighting the need for new therapies. Moreover, the identity of the AML cell of origin is obscure. AML research, however, is hampered by the lack of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.